PPAR-gamma agonist rosiglitazone stops the progressive dopaminergic degeneration induced by chronic MPTP in mice

被引：0
|
作者：
Carta, A. [1 ]
Frau, L. [1 ]
机构：
[1] Univ Cagliari, Toxicol, Cagliari, Italy
来源：
PARKINSONISM & RELATED DISORDERS | 2009年 / 15卷
关键词：
D O I：
10.1016/S1353-8020(09)70473-0
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.122
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [31] Peroxisome proliferator-activated receptor gamma (PPAR-gamma) activator, rosiglitazone, improves vascular structure and reduces lipid deposition in atherosclerotic Mthfr knock-out mice
    Savoia, C.
    Lemarie, C.
    Ebrahimian, T.
    Touyz, R. M.
    Schiffrin, E. L.
    EUROPEAN HEART JOURNAL, 2008, 29 : 865 - 865
  • [32] PPAR-gamma agonist rosiglitazone restores impaired in vivo reendothelialization capacity of endothelial progenitor cells in patients with diabetes: critical role of NAD(P)H oxidase and NO availability
    Sorrentino, S.
    Bahlmann, F.
    Besler, C.
    Mueller, M.
    Fliser, D.
    Haller, H.
    Drexler, H.
    Landmesser, U.
    EUROPEAN HEART JOURNAL, 2006, 27 : 132 - 132
  • [33] PPAR-gamma agonist pioglitazone improves semen quality and testicular histomorphometrics with partial reversal of hyperglycaemia in alloxan-induced diabetic rats
    Akinola, O. B.
    Dosumu, O. O.
    Sanusi, S. A.
    Ajayi, T. F.
    Olajide, T. H.
    MIDDLE EAST FERTILITY SOCIETY JOURNAL, 2015, 20 (04) : 271 - 279
  • [34] Emodin alleviates chronic constriction injury-induced neuropathic pain and inflammation via modulating PPAR-gamma pathway
    Badshah, Ismail
    Qazi, Neelum Gul
    Ali, Fawad
    Minhas, Amber Mahmood
    Alvi, Arooj Mohsin
    Kandeel, Mahmoud
    Imran, Muhammad
    ul Hassan, Syed Shams
    Bungau, Simona
    PLOS ONE, 2023, 18 (07):
  • [35] Effects of Angiotensin II Receptor Blocker (ARB) and PPAR-gamma Agonist on Vascular Failure in Patients with Hypertension, Diabetic Mellitus and Chronic Kidney Disease
    Watanabe, Hideki
    Nakagawa, Kunio
    Kakihana, Masaaki
    CIRCULATION, 2008, 118 (18) : S299 - S299
  • [36] Topical application of the PAFR agonist carbamoyl PAF or oral administration of the PPARγ agonist Rosiglitazone suppresses chemical carcinogenesis and chronic PMA-induced inflammation
    Konger, R. L.
    Sahu, R. P.
    DaSilva, S.
    Travers, J. B.
    Rezania, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 : S29 - S29
  • [37] PREVENTION OF PERINATAL NICOTINE EYCPOSURE-INDUCED ALTERATIONS IN AIRWAY CONSTRICTION BY PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARγ) AGONIST ROSIGLITAZONE
    Liu, J.
    Sakurai, R.
    Torday, J. S.
    Rehan, V. K.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2010, 58 (01) : 225 - 225
  • [38] PPARγ Agonist Rosiglitazone and Antagonist GW9662: Antihypertensive Effects on Chronic Intermittent Hypoxia-Induced Hypertension in Rats
    Zhang, Ningzhi
    Wei, Feng
    Ning, Sisi
    Hu, Jialu
    Shi, Hongtao
    Yao, Zhifeng
    Tang, Minna
    Zhang, Yongqiao
    Gong, Jiaxin
    Ge, Junbo
    Cui, Zhaoqiang
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2024, 17 (04) : 803 - 815
  • [39] The α7 nAChR Agonist PNU-282987 Reduces Inflammation and MPTP-Induced Nigral Dopaminergic Cell Loss in Mice
    Stuckenholz, Vanessa
    Bacher, Michael
    Balzer-Geldsetzer, Monika
    Alvarez-Fischer, Daniel
    Oertel, Wolfgang H.
    Dodel, Richard C.
    Noelker, Carmen
    JOURNAL OF PARKINSONS DISEASE, 2013, 3 (02) : 161 - 172
  • [40] Further validation of LABORAS™ using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration
    Quinn, Leann P.
    Stean, Tania O.
    Chapman, Helen
    Brown, Matthew
    Vidgeon-Hart, Martin
    Upton, Neil
    Billinton, Andrew
    Virley, David J.
    JOURNAL OF NEUROSCIENCE METHODS, 2006, 156 (1-2) : 218 - 227
12345